Download PDF

1. Company Snapshot

1.a. Company Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.


Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease.4D Molecular Therapeutics, Inc.has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.


The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.


Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease.4D Molecular Therapeutics, Inc.has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.


The company was founded in 2013 and is headquartered in Emeryville, California.

Show Full description

1.b. Last Insights on FDMT

Negative drivers behind 4D Molecular Therapeutics, Inc.'s recent performance include multiple law firm investigations into potential securities fraud, which may have led to increased uncertainty and volatility. Pomerantz LLP has been investigating claims on behalf of investors since mid-January 2025, advising them to contact the firm regarding potential legal action. These ongoing investigations may have negatively impacted investor sentiment, contributing to the company's recent struggles.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov -22

Source: seekingalpha.com

Card image cap

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov -20

Source: globenewswire.com

Card image cap

4DMT Appoints Kristian Humer as Chief Financial Officer

Nov -17

Source: globenewswire.com

Card image cap

4DMT Announces New Employment Inducement Grants

Nov -14

Source: globenewswire.com

Card image cap

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

Nov -10

Source: zacks.com

Card image cap

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov -10

Source: globenewswire.com

Card image cap

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov -06

Source: globenewswire.com

Card image cap

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Nov -06

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Gene Therapeutic Products

Expected Growth: 11.3%

4D Molecular Therapeutics, Inc.'s gene therapeutic products are driven by increasing demand for novel treatments, advancements in gene editing technologies, and a growing understanding of genetic diseases. The company's proprietary vector platform and strong pipeline of product candidates also contribute to its 11.3% growth.

7. Detailed Products

Therapeutic Products

4D Molecular Therapeutics, Inc. develops and commercializes gene therapies for rare genetic diseases and other serious conditions.

Vector Platform

A proprietary adeno-associated virus (AAV) vector platform designed to optimize gene therapy delivery and expression.

Directed Evolution

A proprietary technology platform that uses directed evolution to engineer AAV vectors with improved properties.

Gene Therapy Candidates

A pipeline of gene therapy candidates in various stages of development for the treatment of rare genetic diseases.

8. 4D Molecular Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for 4D Molecular Therapeutics, Inc. is medium due to the presence of alternative gene therapy approaches and emerging technologies.

Bargaining Power Of Customers

The bargaining power of customers for 4D Molecular Therapeutics, Inc. is low due to the company's specialized gene therapy products and limited competition.

Bargaining Power Of Suppliers

The bargaining power of suppliers for 4D Molecular Therapeutics, Inc. is medium due to the company's dependence on a few key suppliers for raw materials and equipment.

Threat Of New Entrants

The threat of new entrants for 4D Molecular Therapeutics, Inc. is high due to the growing interest in gene therapy and the potential for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry for 4D Molecular Therapeutics, Inc. is medium due to the presence of established competitors in the gene therapy market and the company's need to differentiate itself.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 4.55%
Debt Cost 3.95%
Equity Weight 95.45%
Equity Cost 18.61%
WACC 17.95%
Leverage 4.77%

11. Quality Control: 4D Molecular Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Daré Bioscience

A-Score: 4.8/10

Value: 10.0

Growth: 6.9

Quality: 8.6

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Quantum-Si

A-Score: 4.3/10

Value: 7.0

Growth: 4.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Avid Bioservices

A-Score: 3.6/10

Value: 4.2

Growth: 4.4

Quality: 1.4

Yield: 0.0

Momentum: 7.5

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Voyager Therapeutics

A-Score: 3.4/10

Value: 7.8

Growth: 4.8

Quality: 5.0

Yield: 0.0

Momentum: 1.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
4D Molecular Therapeutics

A-Score: 2.9/10

Value: 7.0

Growth: 1.3

Quality: 3.6

Yield: 0.0

Momentum: 4.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Keros Therapeutics

A-Score: 2.6/10

Value: 5.8

Growth: 0.3

Quality: 6.8

Yield: 0.0

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

10.7$

Current Price

10.7$

Potential

-0.00%

Expected Cash-Flows